瑞德西韦(remdesivir)抗冠状病毒应用前景

Remdesivir prospect of anti-coronavirus effect

瑞德西韦是腺苷类似的氨基磷酸酯前体药,RNA依赖性的RNA聚合酶(RNA-dependent RNA-polymerases,RdRp)抑制剂,在细胞试验和动物试验中,它对RNA病毒(如MERS和SARS)具有广谱抗病毒活性,且毒性低。作为治疗2019新型冠状病毒(2019 novel coronavirus,2019-nCoV)感染的潜在药物,目前已在中国开展Ⅲ期临床试验。本文就该药物抗病毒机制、体外抗病毒活性、动物实验、毒理实验、药动学和已进行的临床研究情况等进行全面综述,供临床参考。

Remdesivir is a phosphoramidate prodrug of an adenine derivative,an RNA-dependent RNApolymerases(RdRp)inhibitor.Remdesivir has broad-spectrum activities against RNA viruses such as MERS and SARS virus in cell cultures and animal models.As a potential drug for the treatment of 2019 novel coronavirus(2019-nCoV)infections,two phase III trials were initiated in early February this year to evaluate the efficacy and safety after intravenous administration in patients infected with 2019-nCoV.This review will focus on the antiviral mechanism,in vitro antiviral activity,animal experiments,toxicology,pharmacokinetics,and clinical studies of remdesivir to help clinicians gain a better understanding to the agent.